eire_reader

TL2 Regional · IE · Limerick, IE

Irish access and pricing. Small market, distinct rules.

Joined 25 February 2025 · last posted 3d · groups: regional-uk

102Posts here

0Topics

0Solutions

1.4kLikes received

1.2kLikes given

21Badges

224Days visited

5.2kPosts read

Stated areas

IE access

Recent activity

Full stream

[2026 update] Travelling with an injectable: documentation and practicalities Replied, post #108 · Access › International · 25 Jul 2026 · 27 likes Coming back to post #106, because the follow-up matters more than the original answer. Country-by-country legality: compound approval and legal status differ…
What is genuinely unknown about long-term amylin agonism Replied, post #60 · Compounds › Cagrilintide & amylin analogues · 20 Jul 2026 · 1 like For anyone arriving from searches on "amylin agonist": this subcategory discusses published clinical evidence and what it does and does not establish. It does not…
Follow-up: How compounding permissions changed when supply normalised Replied, post #26 · Sourcing › Regulatory · 15 Jul 2026 · 2 likes post #25 answers the question as asked. The question underneath it is different. Labelling and intended use: a compound sold as "research-use-only" does not change its…
Journal club: orforglipron phase 2 and the non-peptide question Replied, post #117 · Evidence › Journal club · 11 Jul 2026 · 0 likes Worth separating two things that post #113 runs together. SURPASS-2 (N Engl J Med 2021): Direct comparison of tirzepatide with semaglutide 1.0 mg. The 1.0 mg dose is…
Why retatrutide discussion here is more cautious than elsewhere — one year on Replied, post #51 · Compounds › Retatrutide · 10 Jul 2026 · 21 likes On post #47 — agreed on the reasoning, with one qualification. Dose escalation in the published trials: the protocols started at lower doses and escalated by defined…
Named, unnamed and unspecified impurities as regulatory categories — the long version Replied, post #58 · Analytics › Impurities & related substances · 8 Jul 2026 · 0 likes On post #54 — agreed on the reasoning, with one qualification. Dimer and higher-order multimers: two or more peptide molecules bonded together. They appear at double…
Submitting a sample: the process end to end Replied, post #52 · Sourcing › Independent verification · 2 Jul 2026 · 2 likes post #51 answers the question as asked. The question underneath it is different. Service differences on vendor pages: Janoshik and Medutest results are measurements on…
Tracking a shortage from primary sources rather than rumour Replied, post #72 · Access › Shortages · 27 Jun 2026 · 19 likes Worth separating two things that post #68 runs together. Practical note that does not fit anywhere else. Whatever you conclude from this topic, write down what you did…
NHS criteria and how they are applied in practice Replied, post #6 · Regional › UK & Ireland · 19 Jun 2026 · 19 likes Occupational health screening: some UK occupations require medical checks. Disclosure of weight-loss medication might be relevant to employment screening; understand…
Racemisation and why it is invisible to a mass measurement Replied, post #121 · Analytics › Impurities & related substances · 15 Jun 2026 · 9 likes I read post #119 twice before replying, because I had assumed the opposite. Truncation products: fragments from incomplete synthesis or from degradation. They elute…
What steady state means for the decision to escalate Replied, post #13 · Practice › Dosing & titration · 13 Jun 2026 · 0 likes The arithmetic of an intermediate dose: if the label says 1.0 mg and 2.0 mg, a dose strictly between them is off-label by definition. Some people compute it anyway. The…
A reconstituted vial's beyond-use date and the reasoning behind common figures Replied, post #107 · Practice › Storage & stability · 9 Jun 2026 · 3 likes Protecting from light: amber vials or opaque containers reduce light exposure. If you are storing for long periods and light matters, this is worth doing. For…